Psychedelic-Assisted Therapies: Research, Regulation, and Clinical Outcomes

Emerging research on psychedelic-assisted therapies is gaining global attention for treatment-resistant depression, PTSD, and substance use disorders. Controlled clinical trials involving compounds such as psilocybin and MDMA demonstrate promising outcomes when administered under structured therapeutic supervision. These treatments aim to enhance neuroplasticity and emotional processing within guided psychotherapeutic frameworks. Regulatory pathways are evolving as evidence accumulates, emphasizing safety protocols, clinician training, and ethical standards. Ongoing research seeks to clarify dosing strategies, long-term effects, and patient selection criteria. With appropriate oversight, psychedelic-assisted interventions may represent a transformative advancement in psychiatric therapeutics.

    Related Conference of Psychedelic-Assisted Therapies: Research, Regulation, and Clinical Outcomes

    February 16-17, 2026

    6th Annual Congress on Mental Health

    Paris, France
    February 16-16, 2026

    43rd Global Psychiatry and Mental Health Conference

    Paris, France
    March 09-10, 2026

    7th Annual Congress on Psychiatry

    Singapore City, Singapore
    March 23-24, 2026

    4th World Congress on Psychiatry

    Tokyo, Japan
    April 13-14, 2026

    8th International Congress on Mental Health

    Tokyo, Japan
    April 20-21, 2026

    33rd World Psychiatrists and Psychologists Meet

    Rome, Italy
    May 27-28, 2026

    8th European Autism Congress

    Paris, France
    June 01-02, 2026

    11th International Conference on Addiction Therapy

    Zurich, Switzerland
    October 19-20, 2026

    6thAnnual Congress on Mental Health & Psychiatry

    Paris, France

    Psychedelic-Assisted Therapies: Research, Regulation, and Clinical Outcomes Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in